AML
51 programs · 50 companies
Programs
51
Companies
50
Trials
46
MOAs
34
TYK2iKRASG12DiEGFRiWRNiJAK1/2iPARPiBCMA ADCPRMT5iCFTRmodMALT1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-2473 | Phase 1/2 | Nectin-4 | ||
| Zanusertib | Approved | PCSK9 | ||
| GIL-8529 | Phase 1/2 | JAK1 | ||
| VRT-5853 | Phase 3 | Aβ | ||
| Fixamavacamten | Phase 2 | SOS1 | ||
| 452-308 | NDA/BLA | TNFα | ||
| 451-4848 | Preclinical | TIM-3 | ||
| Voxanaritide | Approved | SGLT2 | ||
| DAN-IIT-515 | Preclinical | TYK2 | ||
| FRE-IIT-769 | Phase 2/3 | PLK4 | ||
| KAR-3569 | NDA/BLA | CDK2 | ||
| EQR-8061 | Phase 1 | BCL-2 | ||
| Olpaosocimab | NDA/BLA | CD47 | ||
| Zorilemzoparlimab | Approved | CDK2 | ||
| Kemaratamab | Phase 1/2 | PARP | ||
| Olpasertib | Phase 3 | DLL3 | ||
| BLP-8787 | Approved | TIM-3 | ||
| XBI-3618 | Phase 1 | GIP-R | ||
| TRV-9337 | Approved | CDK4/6 | ||
| AMP-408 | Phase 1/2 | AuroraA | ||
| Motanaritide | Approved | FLT3 | ||
| GAL-555 | Phase 3 | C5 | ||
| G1-8409 | Phase 3 | Cl18.2 | ||
| Sovaosocimab | Phase 1 | PRMT5 | ||
| GEN-5535 | Phase 1 | APOC3 | ||
| MED-3086 | Preclinical | CFTR | ||
| Mavubrutinib | Phase 3 | GLP-1R | ||
| Mirirasimod | Approved | FLT3 | ||
| Zenoglumide | Phase 2 | USP1 | ||
| SON-6232 | Phase 2/3 | SHP2 | ||
| Rilucapivasertib | Phase 2/3 | GLP-1R | ||
| LMN-9194 | Approved | FGFR | ||
| FDM-9341 | Phase 2/3 | JAK1 | ||
| EGR-8971 | Phase 1 | SMN2 | ||
| GH-9188 | Phase 1 | CDK4/6 | ||
| TAI-4908 | Phase 3 | Menin | ||
| REC-373 | Phase 1 | SGLT2 | ||
| CHI-2221 | Phase 3 | SOS1 | ||
| XER-568 | Phase 1 | Aβ | ||
| FYB-7121 | Phase 1/2 | CD20 | ||
| ESC-346 | Phase 1 | WEE1 | ||
| Cevirelsin | Phase 2 | TYK2 | ||
| Capiderotide | NDA/BLA | PSMA | ||
| Tezesacituzumab | Phase 2 | C5 | ||
| TEV-7734 | Approved | KRASG12C | ||
| Semacapivasertib | Preclinical | CDK4/6 | ||
| Fixatuximab | Phase 1/2 | Cl18.2 | ||
| Kemaderotide | Approved | AuroraA | ||
| CST-7277 | Phase 2/3 | CD123 | ||
| Semazasiran | NDA/BLA | IL-23 | ||
| VEE-8520 | NDA/BLA | ALK |
Trials (46)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06839922 | MRK-2473 | Phase 1/2 | Recruiting |
| NCT03883596 | Zanusertib | Approved | Recruiting |
| NCT04329743 | VRT-5853 | Phase 3 | Not yet recr... |
| NCT08909471 | 452-308 | NDA/BLA | Active |
| NCT05216372 | 452-308 | NDA/BLA | Completed |
| NCT05414475 | Voxanaritide | Approved | Recruiting |
| NCT07587164 | Voxanaritide | Approved | Completed |
| NCT03918975 | Voxanaritide | Approved | Not yet recr... |
| NCT06082497 | DAN-IIT-515 | Preclinical | Terminated |
| NCT03556730 | FRE-IIT-769 | Phase 2/3 | Terminated |
| NCT05663987 | Olpaosocimab | NDA/BLA | Recruiting |
| NCT07367541 | Zorilemzoparlimab | Approved | Not yet recr... |
| NCT06146108 | BLP-8787 | Approved | Terminated |
| NCT04378203 | TRV-9337 | Approved | Completed |
| NCT05905201 | TRV-9337 | Approved | Active |
| NCT08557357 | TRV-9337 | Approved | Terminated |
| NCT08763510 | Motanaritide | Approved | Not yet recr... |
| NCT04561391 | GAL-555 | Phase 3 | Recruiting |
| NCT06720586 | G1-8409 | Phase 3 | Completed |
| NCT08148854 | Sovaosocimab | Phase 1 | Not yet recr... |